## **Scope of Practice for Pharmacists in Canadian Jurisdictions**

Table One: Pan-Canadian Overview, Effective August 2023

	Prescribing in the absence of an existing prescription				Prescribing when there is an existing prescription				Tests			KEY
	Initiate a prescription	Initiate a Rx under delegation/	Initiate a Rx for specified conditions/	Prescribe in emergency	Adapt: change dose, formulation,	Therapeutic substitution	Renew/ continue a Rx for continuing	Administer: includes parenteral and non-	Order lab tests	Perform tests	Interpret tests	Established in legislat and regulation or Canadian Armed Forces policy
	procemption	collective Rx		circumstances	duration, route		care	parenteral				Pending – Legal authorization received
AB	<b>1</b>	1	1		<b>V</b>	<b>V</b>		1, 3	<b>Ø</b>			infrastructure/framew required to fully imple
BC			1		<b>2</b> 3	3	3	1, 3		3		this activity not yet in place
CF		<b>v</b>	<b>v</b>		<b></b>	<b>v</b>			5		5	<ol> <li>Additional formal training/ authorization from regulator required</li> </ol>
MB	1, 3, 4		<b>1</b>	3	<b>V</b>	6	3	2, 3	1, 3, 7	3	3	
NB	4		1		<b>v</b>	<b></b>		2, 3	P	3		<ul> <li>Additional formal training/ authorization from regulator required in certain circumsta only</li> <li>Further limitations on types/ classes of medication, patie groups or circumstances ex</li> <li>Activity can only be conduction</li> </ul>
NL			1		1	<b>1</b>	1	1, 3		3	3	
NS	4		<b>v</b>		<b>3</b>	<b>~</b>	3	2, 3	<b>Ø</b>	3		
NT							3					
NU											within the terms of a formal collaborative practice agree	
ON					<b></b>			1, 3	3	3	3	or approved collaborative se environment
PE			2		<b>Ø</b>	<b>V</b>	2	2, 3	6	3		5 Under delegation for the Canadian Armed Forces (CF
QC	4		2	3	<b>V</b>			1, 3		3		Health Services 6 Hospital practice only
SK	2, 3		2, 3		3	2, 3		1, 3	6	3	3	7 Currently being phased-in
YT			1					2, 3				Rx Prescription

Note: This chart is a summary only for the purpose of comparing jurisdictions and is not meant to replace provincial/territorial-specific information. Pharmacy professionals are expected to consult all relevant jurisdictional laws, regulations, standards and other rules and requirements related to scope of practice in their particular jurisdiction.

Note: This chart outlines the scope of practice for pharmacists when providing care for human patients. Readers are referred to provincial/territorial legislation for more information on the scope of practice when providing care for animal patients.




National Association of Pharmacy Regulatory Authorities ® Association nationale des organismes de réglementation de la pharmacie











ng/ llator umstances



nducted rmal greement ive setting/



-in

## **Scope of Practice for Pharmacists in Canadian Jurisdictions** Table Two: Definitions used to describe the pharmacist scope of practice

\*Note: Authorized prescriber includes any regulated health professional who is authorized to prescribe and is practising within their professional scope of practice.

Group	Category	Term and Definition
Prescribing in the absence of an existing prescription		Prescribing that is based on assessment of the prescriber. The pharmacist is responsible for providers. The pharmacist has met and practise registration with the PRA for additional prescrib
	Initiate a prescription	Generating a new prescription for a prescription management required. Prescribing authority n legislation or PRA standards/directives/guidelin written agreement or approval of the practice
	Initiate a prescription under delegation/collective Rx	The pharmacist is authorized to generate a ne collective prescription provides the pharmacis considered part of the independent scope of p
	Initiate a prescription for specified conditions/ circumstances	Generating a new prescription for a prescription standards/directives/guidelines. These may in previously diagnosed conditions, conditions th
	Prescribe in emergency circumstances	Prescribing a prescription drug, in the absence it is not reasonable for the patient to seek eme
Prescribing where there is an existing prescription		Prescribing for the purpose of optimizing care prescribing, but ensures collaboration with the by the PRA.
	Adapt a prescription	Modifying or altering an existing prescription v
	Therapeutic substitution	Substituting a prescribed drug with a different
	Renew/continue a prescription for continuing care	Prescribing a prescription drug that has been
Administer		Administering a drug (substance) by parentera
Tests	Order lab tests	Ordering a laboratory analysis within the pract
	Perform tests	Performing a laboratory test or point of care te
	Interpret tests	Interpreting test results within the practice of
<ol> <li>Additional formal training/ authorization from regulator required</li> </ol>		The pharmacist is required by the PRA to under PRA prior to undertaking these activities. This practice designations, or an indication on the words, if training is mandatory for licensure, it
3 Further limitations on types/classes of medication, patient groups or circumstances exist		The pharmacist's ability to perform the activity (e.g., restrictions on age for administration of of the column as defined above.
4 Activity can only be conducted within the terms of a formal collaborative practice agreement or approved collaborative setting or environment		The activity can only be conducted within a conception only be conducted within a conception of the collaboration with an authorized prescriber. The pharmacist is reconstructed prescriber. The provision with an authorized prescriber.



National Association of Pharmacy Regulatory Authorities Association nationale des organismes de réglementation de la pharmacie

ne patient's condition and judgment by the pharmacist. The pharmacist is not in possession of an original prescription from an authorized or decisions about the clinical management including prescribing a drug, but ensures collaboration with the patient's other healthcare ises in accordance with the requirements set by the pharmacy regulatory authority (PRA). Requirements may include but are not limited to ribing authorization or prescribing in a collaborative practice or prescribing for specified conditions/circumstances, etc.

tion drug where the pharmacist is responsible for the assessment of patients and the decisions made about the drug and the clinical may be restricted by the pharmacist's specialty and competency, but not to specific medical conditions/circumstances outlined in lines. While it is always expected that pharmacists will only prescribe within a collaborative practice relationship/environment, a formal e environment/setting by the PRA is only required when indicated with a footnote.

new prescription for a prescription drug only through delegation or in accordance with a collective prescription. The delegation/ ist with authorization to prescribe according to the conditions of the delegation/collective prescription, but this activity is not practice of the pharmacist.

tion drug for medical conditions or circumstances which have been approved by the PRA and are outlined in legislation or PRA include but are not limited to emergency contraception, smoking cessation, minor/common ailments, self-diagnosed conditions, that do not require a diagnosis, prevention of diseases.

ce of an existing prescription, when there is an immediate need for drug therapy and in the professional judgment of the pharmacist, nergency health care elsewhere and there is a risk to the patient's health if immediate treatment is not provided (e.g., asthma attack).

re or continuing care based on assessment of the patient and judgment by the pharmacist. The pharmacist is responsible for the ne patient's primary and other healthcare providers. The pharmacist has met and practices in accordance with the requirements set

with respect to the dose, formulation/dosage form, dosage regimen, route of administration, or duration to optimize therapy.

nt chemical entity that has or is expected to have an equivalent therapeutic effect.

previously prescribed for the purpose of continuing therapy based on assessment of the patient and judgment by the pharmacist.

ral or non-parenteral routes of administration.

ctice of pharmacy.

test (POCT) within the practice of pharmacy.

pharmacy.

dergo and demonstrate completion of a training program approved by the PRA and/or must receive additional authorization from the could include additional requirements for approved injection training program, additional prescribing authority, extended or advanced licence that additional training has been completed. This only includes training over and above that required for licensure. In other it is not noted in the chart.

ity is restricted to certain patient groups, certain types/classes of medications, certain medical conditions or certain situations of vaccines in most provinces, etc.). Note: This footnote is only used for further restrictions beyond those indicated by the title

collaborative practice setting or environment that has been approved by the PRA and/or within the terms of a written formal responsible for the assessment of patients and the decisions made about the drug and the clinical management required in The prescribing may be restricted by the parameters of the collaborative agreement or the protocols of the collaborative setting/ nditions/circumstances outlined in legislation or PRA standards, directives or guidelines.





